MSLN and neoplasm: Molecular imaging with 89Zr-PET has been utilized in a phase I study to determine target antigen mesothelin expression, anti-mesothelin antibody tumor uptake, organ distribution at the whole body level, and the relationship between uptake and response to treatment in patients with advanced pancreatic and ovarian cancer.